TNFRSF1B and myeloid sarcoma: It remains a possibility that pan-TNF targeting strategies, which have resulted in the promotion or exacerbation of disease in MS patients, have failed due to their inability to leave protective TNFR2 functioning whilst targeting only the pro-inflammatory TNFR1 pathway.